

Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

## Press Release



### ASKA Executes Capital Increase to FTS AMBROSE HOLDINGS, INC.

**TOKYO, April 20, 2026** – ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886, Head Office: Tokyo/ President, Representative Director: Sohta Yamaguchi) announced that the Company has increased its stake in FTS AMBROSE HOLDINGS, INC. (hereinafter, FTS), an equity method affiliate that holds a 100% stake in its Philippine strategic partner MEDCHOICE PHARMA HOLDINGS, INC. (hereinafter, MC), from 21% to 30% through an additional 9% investment as of April 14, 2026.

#### 1. Purpose of the additional investment

The Group has identified global business as one of its key strategies in its Medium-Term Management Plan. Through this additional investment, the Company will strengthen our partnership with MC, under FTS, and pursue synergies through collaboration in specialty areas such as thyroid and obstetrics & gynecology, thereby striving to develop its global business.

#### 2. Number of shares acquired, and status of shares held before and after acquisition

(1) Number of shares held before the transaction:	3,675 shares (holding ratio of voting rights: 21%)
(2) Number of shares acquired:	1,575 shares
(3) Number of shares held after the transaction:	5,250 shares (holding ratio of voting rights: 30%)

#### 3. Overview of FTS AMBROSE HOLDINGS, INC.

(1) Trade name	FTS AMBROSE HOLDINGS, INC.	
(2) Location	201 Dingalan St., Ayala Alabang, Muntinlupa City	
(3) Title and name of representative	Chairman, Ambrosio V. Padilla III	
(4) Business	Holding company of MEDCHOICE PHARMA HOLDINGS, INC.	
(5) Capital	1.8 million Philippine peso (4.6 million Japanese yen)	
(6) Establishment	October 27, 2003	
(7) Major Shareholders and Shareholding Ratio	Ambrosio V. Padilla III, Shareholding Ratio: 12%	
(8) Relationship between the Company and FTS	Capital relationship	Not applicable
	Personal relationship	Not applicable
	Business relationship	Not applicable

(9) Consolidated financial results and consolidated financial position of MEDCHOICE PHARMA HOLDINGS, INC. for the past three years			
Fiscal Year	FY ended Dec. 31, 2022	FY ended Dec. 31, 2023	FY ended Dec. 31, 2024
Consolidated net assets	1,604 million yen	1,932 million yen	2,100 million yen
Consolidated total assets	2,510 million yen	2,710 million yen	2,740 million yen
Consolidated net sales	2,338 million yen	2,560 million yen	2,900 million yen
Profit	532 million yen	575 million yen	734 million yen

Calculated at 2.65 yen per Philippine peso.

---

**Media Contacts**

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: [kouhou@aska-pharma.co.jp](mailto:kouhou@aska-pharma.co.jp)